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Abstract: This review summarizes the current state of knowledge about the metabolism of cancer cells,
especially with respect to the “Warburg” and “Crabtree” effects. This work also summarizes two key
discoveries, one of which relates to hexokinase-2 (HK2), a major player in both the “Warburg effect”
and cancer cell immortalization. The second discovery relates to the finding that cancer cells, unlike
normal cells, derive as much as 60% of their ATP from glycolysis via the “Warburg effect”, and the
remaining 40% is derived from mitochondrial oxidative phosphorylation. Also described are selected
anticancer agents which generally act as strong energy blockers inside cancer cells. Among them,
much attention has focused on 3-bromopyruvate (3BP). This small alkylating compound targets both
the “Warburg effect”, i.e., elevated glycolysis even in the presence oxygen, as well as mitochondrial
oxidative phosphorylation in cancer cells. Normal cells remain unharmed. 3BP rapidly kills cancer
cells growing in tissue culture, eradicates tumors in animals, and prevents metastasis. In addition,
properly formulated 3BP shows promise also as an effective anti-liver cancer agent in humans and
is effective also toward cancers known as “multiple myeloma”. Finally, 3BP has been shown to
significantly extend the life of a human patient for which no other options were available. Thus, it
can be stated that 3BP is a very promising new anti-cancer agent in the process of undergoing
clinical development.
Keywords: 3-bromopyruvate; antitumor therapy; Warburg effect; Crabtree effect; oxidative phosphorylation;
glutathione; buthionine sulphoximine
1. Introduction
The “Warburg Effect” is cancers’ oldest known hallmark, i.e., aberrant sugar (glucose) metabolism
to lactic acid even in the presence of oxygen. The renowned scientist Otto Warburg working in Berlin,
Germany during the early part of the past century made two key experimental discoveries as follows:
Molecules 2016, 21, 1730; doi:10.3390/molecules21121730 www.mdpi.com/journal/molecules
Molecules 2016, 21, 1730 2 of 15
(1) Cells from most cancers, regardless of the tissue of origin, exhibit a very intense sugar (glucose)
consumption which may exceed 10-fold that of normal cells [1].
(2) This results in an elevated production and extrusion of lactic acid even in the presence of
oxygen [1].
The net result of these two observations, i.e., “high level of glycolysis in cancer cells even in
the presence of oxygen”, is now commonly and appropriately referred to as the “Warburg effect”.
Following the subsequent discovery 18 years later that mitochondria are the site of ATP synthesis
by oxidative phosphorylation [2,3], Warburg assumed that the high aerobic glycolysis that he
and colleagues had observed previously in many cancers resulted from the lowered capacity of
mitochondria to utilize oxygen, and may be a putative cause of cancer [4]. Although neither assumption
was completely correct nor incorrect, there was much more to be learned as will be noted below as this
brief review develops.
2. Experimental Knowledge Acquired to Date
2.1. Energy Production Considerations in Normal Cells and Cancer Cells
In most healthy cells, about 90% of the ATP is derived from mitochondrial oxidative
phosphorylation, and only about 10% comes from the metabolism of glucose to pyruvic acid. However,
in rapidly growing cancer cells derived from established tumors, the “Warburg effect”, i.e., high
glycolysis even in the presence of oxygen, may provide up to 60% of the ATP with the remaining
(~40%) being derived from mitochondrial oxidative phosphorylation [5]. Although these percentages
are dependent on growth rate and may differ widely among different types of cancers, it is important
to note that both glycolysis and mitochondria via ATP production are the two vital contributors to
powering cancer growth and metastasis. A very common misconception among those unfamiliar with
cancer metabolism is that most cancerous tumors thrive exclusively off the sugar glucose via glycolysis
for their energy source. In fact, as noted above, most frequently they derive significant amounts
of their energy in the form of ATP from both the “Warburg effect”, as well as from mitochondrial
oxidative phosphorylation.
As stated above, it should be appreciated that the “Warburg effect” allows cancerous tumors
and the viscous cells that comprise them to adapt to hypoxic conditions which frequently develop
during their growth [6]. Although uncommon, there are exceptions as some gliomas, hepatomas,
and breast cancer cell lines are more dependent on mitochondrial oxidative phosphorylation for
their energy source, i.e., ATP [7]. This can be explained by the presence of various bioenergetic
phenotypes from the exclusively glycolytic to highly oxidative phosphorylation [8]. As reviewed
much earlier by co-author Pedersen [9], these cells are usually slow growing. Moreover, Pedersen and
coworkers [8] also have shown in vitro that the most rapidly growing hepatoma tumor is the 3924A
and the slowest growing is the 9618A. The 7800 tumor has an intermediate growth rate. The 3924A
tumor, i.e., the fastest growing, has the highest glycolytic rate. One year later, it was also confirmed
that slowdown in growth of a tumor lowers the rate of glycolysis, and in turn, faster growth intensifies
this process [10]. Apart from the “Warburg effect”, some cancers also exhibit a phenomenon of the so
called “Crabtree effect”. It is short-term and reversible (unlike the “Warburg effect”) and involves the
suppression of respiration and oxidative phosphorylation by a high concentration of glucose [11,12].
This may occur despite the presence of functional mitochondria [11]. There are several hypotheses to
explain the case of inhibition of respiration and oxidative phosphorylation by a high concentration of
glucose [12]. Most likely, in tumor cells this phenomenon is regulated by multifaceted mechanisms [7].
These include inter alia a competition for the free cytoplasmic phosphate pool (Pi) between the
mitochondrial phosphate carrier and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or for
free adenosidne diphosphate (ADP) between the mitochondrial adenine nucleotide translocase and
the pyruvate kinase (PK). This emulation between glycolysis and oxidative phosphorylation can cause
respiratory impairment by increased glucose availability. Furthermore, the important factor might
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be the action of fructose 1,6-biphosphate that inhibits the mitochondrial respiratory complexes III
and IV. This leads to the inhibition of the ATP synthase. It should not be forgotten that the metabolism
of glucose increases the reactive oxygen species (ROS) generation that damages the mitochondrial
membrane and depresses respiration [7]. This phenomenon also was described for “Crabtree positive
yeast”, the cells of which were cultivated in media that contained a high concentration of glucose.
This effect was especially well visible for cells during the logarithmic phase of growth. Inside the
cells which undergo a “Crabtree effect”, respiration and stress response mechanisms are repressed.
As a matter of fact, hexokinase 2 (HK2) is both highly elevated in rapidly growing cancers and is
bound to mitochondrial voltage dependent anion channels (VDAC). When bound to VDAC, the HK2
is not inhibited by its product, i.e., glucose-6-phosphate (G-6-P). Therefore, glycolysis is elevated thus
enhancing this pathway’s ATP production. Consequently, the need for ATP produced by oxidative
phosphorylation, while still taking place to some extent, is suppressed/diminished.
These cells obtain energy mainly by fermentation of glucose. Depletion of glucose forces the cells
to switch to the metabolism of non-fermentable carbon sources [13,14]. Furthermore, in some types of
cancer, lactate released by the hypoxic tumor cell compartment can be transported to the aerobic tumor
cell compartment which undergoes oxidative metabolism. Therefore lactate released by one cell drives
the metabolism of the second cell. This phenomenon called “lactate shuttling” plays an important
role for metabolic symbiosis establishment between glycolytic cells and cells that undergo oxidative
metabolism [15,16]. Moreover, it has been shown many times that cancer cells can reversibly regulate
their energy metabolism. This phenomenon observed in vitro must exist also in vivo. With respect
to the tumor architecture, the metabolic symbiosis may be considered as a niche where a hypoxic
central part utilizes glucose while an edge of the tumor which is better vascularized uses lactate as
a substrate [16]. Therefore, some of the cancer cells within a tumor may have a different phenotype
than the other cells [17]. Thus, the ability of cancer cells to undergo short-term and reversible changes
in their metabolism may also allow them to avoid the toxic effect of a drug. This is possible as it has
been shown in experiments performed in vitro [18,19] that chosen cancer cells are able to overcome
the inhibition of fermentative metabolism. Thus, even very effective known inhibitors of glycolysis are
not sufficient in eliminating cancer cells with changed metabolism. Therefore, the proper targeting of
cancer cells remains an urgent problem [7].
On the other hand, as nutrients are usually in abundance, it has been suggested that cancer
cells do not pursue the most energetically efficient biosynthetic pathways but rather the fastest ways
necessary for rapid proliferation [20]. Not only is the sugar glucose vastly consumed by cancerous cells
exhibiting the “Warburg effect” but also amino acids, mostly glutamine, which in addition to serving
as an energy source [21] is also a source of amine groups essential for many biosynthetic events, e.g.,
production of purines and pyrimidines [22]. In addition, cancer cells may utilize metabolic pathways
that are highly energy producing, e.g., the mitochondrial beta-oxidation of fatty acids [23]. Finally, it is
important to note that the products and intermediates of glycolysis and glutaminolysis are used in the
synthesis of many of the molecules needed for intense proliferation [20].
However, as noted much earlier [9], there is a marked reduction in mitochondria in many rapidly
growing cancers, greatly diminishing their net contribution to the production of ATP essential to
support cell growth and division. Therefore, in such cancers it is important to maintain a high
glycolytic rate. The oxidized form of nicotinamide adenine dinucleotide (NAD+) and the nicotinamide
adenine dinucleotide phosphate (NADPH2) are constantly needed both for the proper functioning
of glycolytic enzymes and to maintain the high glycolytic flux. NAD+, which is necessary for the
action of GAPDH is regenerated mainly by dehydrogenases, e.g., lactate dehydrogenase (LDH) which
simultaneously converts pyruvate into lactate [20].
It was previously thought that pyruvate kinase M2 (PKM2), the embryonic form of this enzyme,
is the form predominantly expressed in cancer cells. However, analyses of PKM1 and PKM2 gene
expression in different cell lines did not confirm this [24]. Nevertheless, the activity of PKM is usually
increased in cancer cells consistent with their upregulated glycolysis. PKM2 activity may be increased
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by its tetramerization and phosphorylation [25] rather than overexpression. It was also shown that
the transition of PKM2 to PKM1 on the expression level diminishes the Warburg effect [15,26]. On the
level of individual cells, the decrease of this cytosolic enzyme activity correlates with the activity of
glycolytic enzymes, i.e., HK2 and GAPDH. Thus, this leads to decreasing of the lactate rate production
in the presence of oxygen, what is very important for the functioning of tumor cells. Consequently,
this phenomenon significantly reduces the growth rate of cancer cells [15,26–28].
A significant amount of pyruvate for LDH comes also from glutaminolysis and transamination of
alanine [6]. The pyruvate dehydrogenase (PDH) in cancer cells exists in the phosphorylated inactive
state. Therefore, most of the pyruvate becomes a substrate for LDH [29].
It has also been shown that a high lactate production induces overexpression of mono-carboxylate
transporters (MCTs) in order to extrude excessive lactic acid and avoid cytoplasm acidification [30].
This leads to acidification of the tumor’s local environment resulting in degeneration of surrounding
tissue and likely promotes invasion and metastasis [31]. Also, the extracellular lactate may be taken up,
presumably also by MCTs, and utilized by other cancer cells possessing functional mitochondria [32,33].
Recently, the role of MCTs in human cancers has been reviewed [30].
Although much has been learned about the underlying molecular basis of the “Warburg effect”
complete agreement on some aspects of this common cancer phenotype is lacking. Generally, it is
assumed that the “Warburg effect” results from an increased glucose uptake together with glycolysis
up-regulation and mitochondrial metabolism down-regulation [11,34]. It is often the case that substrate
availability is the only limiting factor for a catalytic reaction and even a whole subsequent pathway.
Therefore, it could be argued that an increased expression of glucose transporters (GLUTs) may be
responsible, at least in part, for the “Warburg effect”. In fact, it was recently shown that the GLUT1 and
GLUT3 transporters are overexpressed in numerous cancers [35]. However, it is also possible that the
latter may be just one of the consequences of the “Warburg effect” [36]. Although it seems likely that
the overexpression of one or more of the enzymatic participants involved in the glycolytic pathway,
e.g., hexokinase (HK), phosphofructokinase (PFK), PK, and LDH contribute to the “Warburg effect”, it
seems clear that mitochondrial bound hexokinase is essential [37,38]. In fact, it was shown in the latter
study [38] that the addition of tumor mitochondria (from Ehrlich ascites cancer cells) containing bound
hexokinase to liver cytosol lacking mitochondria and exhibiting no capacity to catalyze glycolysis,
results in a glycolytic rate as high as that found in the cancer cells under study. Later the isoform
involved was identified as HK2 [39]. It is now known that HK2 is highly expressed in most cancers
whereas in most normal cells the predominant isoforms used are HK1, HK4, and to a lesser extent
HK2 and HK3 [7].
In addition to being highly expressed in cancer cells and playing the major role in the
“Warburg effect”, it is known also from an earlier collaborative project involving co-author Pedersen
that the mitochondrial binding of hexokinase (now known to be HK2) is bound to the outer membrane
protein VDAC [40]. This localization of HK2 gives it preferred access to ATP produced during
oxidative phosphorylation [41], and unlike other hexokinase isoforms, causes it to become insensitive
to inhibition by its product, G-6-P [42,43].
Abnormal expression of PFK was also shown in some cancer cell types. For example, leukemia
and lymphoma cells express PFK isoforms which normally are exclusively expressed in liver and
platelets. These isoenzymes, expressed in increased amounts, show a much lower sensitivity to
inhibition and are easily activated even at low concentrations of 2,6-bisphosphate [44]. Other possible
contributors to the Warburg effect may exist also at the level of pyruvate metabolism, i.e., its lowered
transport into mitochondria, decreased activity of PDH and/or increased activity of LDH [7].
HIF-1α (hypoxia inducible factor-1 alpha) activation also is a contributor to the Warburg effect,
likely at the transcriptional level. HIF-1α is usually activated as a consequence of mutations in
tumor suppressor genes (e.g., P53, P21) [45] and contributes in part to the overexpression of glucose
transporters and several glycolytic enzymes such as HK2, PFK, PKM, and LDH [46]. Perhaps most
notable is the earlier finding that the HK2 promoter is activated seven-fold by hypoxic conditions in
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the presence of the first substrate of glycolysis, i.e., glucose [47]. Moreover, HIF-1α induces expression
of pyruvate dehydrogenase kinase (PDK) [29], which inhibits PDH by its phosphorylation causing the
vast majority of pyruvate to be converted into lactate by LDH. Expression of LDH itself is induced not
only by HIF-1α but also through oncogenes (e.g., c-Myc) [20].
Collectively, in order to proliferate, tumors require large amount of energy in a short period of
time. Consequently, aerobic glycolysis has an advantage as it provides ATP faster than mitochondrial
respiration. All the above-mentioned metabolic changes render cancer cells less dependent on
oxygen availability, support increased proliferation and migration, and help the cells avoid apoptosis
and chemotherapy [6]. Although the consequences of the Warburg effect are clear, it is hard to
unambiguously ascribe any one of the above-described molecular events as its only cause. Nevertheless,
HK2 clearly stands out as the major contributor for the reasons already alluded to above. This and the
fact that HK2 bound to mitochondrial VDAC [40] is also a major contributor to the immortalization of
cancer cells [48,49] makes this isoenzyme one of cancer’s best friends. However, this also makes HK2
one of most vulnerable cancer’s “Achilles heel” and therefore it is a highly promising drug target. It is
also worth mentioning that numerous mutations present in each tumor might come as a secondary side
effect of metabolic changes related to the cancer disease. They arise after the initiation of uncontrolled
growth due to damaged mitochondria [50].
2.2. Anti-Energy Metabolism Inhibitors: An Effective Approach for Treating Cancer
There is a very effective diagnostic technology based on mitochondrial bound HK2, the key player
in the “Warburg effect”. Specifically, the technology referred to as positron emission tomography (PET)
is based on the fact that in cancer cells 2-deoxyglucose (2-DG), a glucose analog, upon entering cancer
cells is phosphorylated by mitochondrial bound hexokinase-2. This yields 2-DG-6-phosphate that
is not further metabolized and thus accumulates in much higher levels than in normal cells. 2-DG
used in PET is labeled with the 18fluorine radioisotope that decays, emitting a positron. This then
annihilates with an electron giving two gamma-photons that are detected by a detector [45]. PET, based
on mitochondrial bound HK2, is one of the most effective methods for imaging solid tumors and as
such serves also as an effective method to screen for anticancer drugs.
2-DG, citrate, and 3-bromopyruvate (3BP) have all been tested recently as potential anticancer
drugs acting either via glycolysis inhibition (2-DG and citrate) or glycolysis plus mitochondrial
inhibition (3BP). It was shown in vitro that 7-days therapy with 5 mM 2-DG resulted in a strong but
incomplete inhibition of growth (60% to over 90%) in 12 different cancer cell lines [51]. A dramatic
100% mortality was shown in the MSTO-211H lung mesothelioma cell line after treating first for 3 days
with 10 mM citrate, a physiological inhibitor of PFK1 [52,53], and then with a low dose of cisplatin [54].
However, it should be noted from all of these studies, and to the best of the authors’ knowledge, that
2-DG, citrate, and cisplatin, each alone have never been shown to quickly eradicate real cancers in
animals. This is in sharp contrast to 3BP, a novel, second-generation glycolysis inhibitor.
In a follow up study on rats, 3BP exhibited high anticancer activity toward quite large advanced
cancers (hepatomas) [55]. In fact, every animal carrying an advanced hepatoma that was treated with
3BP became completely cancer free. Moreover, the cancer never recurred throughout the animals’
lifetime. About 70% of cancer cells were killed after one administration and after 4 weeks of treatment
the tumors in all rats were eradicated without any harm to the animals. Thereafter, they all lived out a
normal life without the return of cancer and died natural deaths. To the authors’ knowledge, in the
long history of cancer research [56], no other anti-cancer agent has been shown to exhibit such striking,
effective, rapid, remarkable, and unexpected results.
In a study published 4 years later [57], co-treatment with cisplatin and 3BP was shown to be
much more efficient than treatment with cisplatin alone. This is probably due to the fact that 3BP
causes ATP depletion leading to inactivation of the mechanism giving resistance to cisplatin, i.e.,
multidrug resistance phenotype (MDR) which is ATP-dependent. Therefore, 3BP is considered as a
powerful multidrug resistance reversal modulator [58]. Considering its lack of evident side-effects [55],
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Ihrlund et al. [57] went on to remark that 3BP is a promising candidate for an anticancer therapeutic,
both alone and in co-treatment with other drugs. This would include both animals and humans
bearing cancers that exhibit positive PET scans.
2.3. Mechanism of Action of 3BP
3BP is a structural analog of pyruvic acid. It is highly reactive, showing strong alkylating
properties toward some proteins/enzymes. The pyruvic chain preferentially and covalently binds
to cysteine(s) of certain proteins, changing their conformation and activity [59]. Finally, the so-called
protein pyruvylation results in alkylation of its active site and the release of a bromide radical [55].
Furthermore, 3BP and its derivatives have been considered as inhibitors of isocitrate lyase and malate
synthase—key enzymes in the glyoxylate pathway that plays an important role in the pathogenesis of
many fungal and bacterial infections, but does not exist in mammalian cells [60].
Although all details of the mechanism of action of 3BP toward mammalian cancer cells are
probably not completely understood, based on all data collected to date, the authors believe that the
simplest mechanism by which this “small molecule” quickly and efficiently kills cancer cells may be
that which is depicted in the “Summary, Proof of Principle” (Figure 1). Here, a cancer cell is shown
producing ATP, its energy source. As indicated in the text, in highly malignant cells, i.e., those that will
likely kill nearly 1 of 2 men and 1 of 3 women, about 60% of the ATP is produced by glycolysis and the
other 40% by the mitochondria [5]. In the cancer cell shown, the anticancer agent 3BP is envisioned to
enter through MCTs, that are involved normally in the efflux of lactic acid out of the cell. It is very
probable that in cancer cells, 3BP uptake is particularly effective because of the overexpression of
MCTs [30]. The entry of 3BP is successfully achieved because lactic acid and 3BP differ in only a single
atom (Br), making it impossible for the cancer cells’ MCTs to distinguish between the two.
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Figure 1. Summary, proof of principle—the simple mechanism by which 3-bromopyruvate (3BP)
quickly and efficiently kills cancer cells through rapid energy depletion.
Some researchers have questioned the important role of MCTs and suggest that a simple diffusion
mechanism may also play a crucial role. Enhanced glycolysis observed inside cancer cells results
in a pH gradient across the cell membrane. This in turn results in 3BP uptake specifically by
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cancer cells [61,62]. However, this role of the pH gradient established by tumor cells should not
be overestimated. Thus, it has been suggested that this phenomenon enhances via MCTs-mediated
transport [62] that could explain the specificity of 3BP’s effect on cancer cells. Then, once inside
the cancer cell, 3BP inhibits its two energy (ATP) production factories, glycolysis and mitochondria.
Normal cells, among them erythrocyte cells, are not harmed by the appropriate 3BP concentration, as
they have a deficiency of MCTs [30,63]. HK2 bound to VDAC initiates cancer cell glycolysis and is likely
one of the most important targets of 3BP as it is known to be inhibited by this agent [64]. Significantly,
at the turn of this new century 3BP was shown to inhibit mitochondrial bound hexokinase [64],
known from the earlier work noted above to be bound to VDAC [40] and to be the HK2 isoform [39].
The mitochondrial phosphate transporter, that is essential for ATP synthesis is also well known to be
inhibited by compounds reacting with sulfhydryl groups (-SH) such as 3BP [65].
The second most important cellular target for 3BP is the GAPDH enzyme [33,66], that like HK2 is
also important for glycolysis. Moreover, this enzyme is overexpressed in many human cancers and its
growing intracellular level positively correlates with tumor progression [67,68].
Regardless of the cell model, 3BP as a very effective inhibitor of glycolysis as well as mitochondrial
ATP synthesis rapidly depletes cellular ATP [55,69,70] and consequently leads to apoptosis [71].
After only 2 h induction in the presence of a defined concentration of 3BP, one can observe characteristic
morphological changes of multiple myeloma (MM) cells indicating an advanced stage of apoptosis.
The cells exhibit some specific changes in morphology characterized by the presence of so-called
“apoptotic bodies” which surround the cells. The studies based on flow cytometry confirmed that
the percentage of apoptotic cells increased with time [72]. Similar results were obtained in the case of
3BP’s effect on hepatocellular carcinoma cells [73,74], and human breast cancer cells [21,75].
The key to understanding the differences in sensitivity toward 3BP in the case of different
eukaryotic cells is the transport of this compound, or more specifically, differences in the level of
the kinetics of 3BP transport in different cell types as already shown [69,76]. For this reason, the
overexpression of MCTs and/or a pH gradient existing across the cell membrane of cancer cells as
a result of over activated glycolysis are the main causes of their high susceptibility to 3BP. This is in
contrast to normal cells. Similar differences in 3BP uptake velocity and the level of accumulation of
this compound inside the cells of taxonomically different fungi were observed earlier [69].
Although the mechanism of action of 3BP is rather complex [70], it is well known that this
compound generates ROS. Studies confirming this were carried out on MM [72], hepatoma [74],
glioma [77], and breast cancer cells [75]. The accumulation of intracellular ROS occurs as the result of
the inhibition of the mitochondrial respiratory chain [74,75]. One of the natural protection mechanisms
of cells against the harmful effects of ROS is a reduced form of glutathione (GSH). For this reason,
susceptibility of cells toward 3BP closely correlates with the natural, intracellular concentration of this
tripeptide thiol [69,72,78]. This was also shown in studies on Saccharomyces cerevisiae mutants with
deleted genes for the glutathione biosynthetic pathway [70]. Furthermore, recent studies show that 3BP
causes a significant decrease in GSH concentration inside fungal, algal, and MM cells while maintaining
the viability of cells similar to the control without 3BP [72]. This phenomenon occurs due to the
GSH-3BP complex formation in order to inactivate this compound [79]. The enzyme that has the ability
to catalyze the conjugation of the reduced form of glutathione to xenobiotic substrates is glutathione
S-transferase (GST). The studies on Cryptococcus neoformans and MM cells demonstrated that under the
influence of 3BP, the expression of the gene encoding this protein increases [72]. The overexpression
of the GST genes leads to an enhancement of GSH-3BP complex formation. Moreover, it was shown
that 3BP alters the level of the expression of genes encoding other crucial enzymes involved in GSH
metabolism (Figure 2). Thus, the overexpression of genes encoding pivotal enzymes for the synthesis
of GSH, γ-glutamylcysteine synthetase (GCL) and glutathione synthetase (GS) were also observed in
response to the strong alkylating action of 3BP.
The increased concentration of GSH is conducive to enhanced inactivation of detrimental drugs.
Accordingly, it is not surprising that 3BP demonstrates synergistic activity with other compounds that
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reduce intracellular levels of GSH. The examples of such compounds which act like GSH depletors are
buthionine sulphoximine (BSO), methionine sulfoximine (MSO), and paracetamol (acetaminophen).
BSO inhibits GCL, MSO irreversible restrains GS effectively blocks GSH synthesis, and paracetamol
is metabolized to cytotoxic N-acetyl-4-benzoquinoneimine (NAPQI) that binds to the GSH [79–83].
Research performed on Saccharomyces cerevisiae and Cryptococcus neoformans confirmed that 3BP and
BSO exhibit a strong synergistic effect [72,76,84]. Summarizing, what is crucial is that 3BP exhibits no
obvious toxicity to healthy cells both in vitro in cell lines [57] and in vivo in animals [55,85]. Moreover,
3BP does not exhibit mutagenic properties in the Ames test [86]. As was shown in the yeast S. cerevisiae
model, 3BP is not extruded by PDR (Pleiotropic Drug Resistance) efflux pumps, and it is unlikely that
cancer cells would develop resistance via the MDR network [76].Molecules 2016, 21, 1730 8 of 14 
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Perhaps most significant is the fact that there is a human case report of 3BP usage as a therapeutic
for primary liver cancer of the fibrolamellar carcinoma form (FLC) [73]. The patient’s doctors had
exhausted commonly used treatment options and decided to use 3BP that had been shown to work well
in an earlier study on hepatoma bearing rats [55]. After treatment of the patient with 3BP, a CT-guided
puncture of ascites fluid showed lack of ascites tumor cells, suggesting that the tumors in the liver
were well encapsulated and dead.
However, rapid destruction of the tumor cells resulted in the overloading of liver’s function.
Almost a year after the beginning of treatment with 3BP and two years after the first diagnosis,
the patient died because of an overload of liver function [73]. Nevertheless, the patient’s life had been
extended enough to allow him to travel to the U.S. with his parents, participate as the patient in a filmed
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clinical correlation lecture at the Johns Hopkins University School of Medicine, Baltimore, MD, and
thereafter to go on an extended vacation with his family prior to returning home to The Netherlands.
2.4. Perspectives
Cancer is the leading cause of death worldwide, accounting for 8.2 million deaths in 2012,
according to the World Health Organization [87]. The chances of acquiring this disease are very high
and it is predicted that one out of two men and one out of three women will die of cancer until the
end of the 21st century [88]. The struggle to find an effective anticancer drug continues. Actually,
one of the most extensively studied anticancer compounds is 3-bromopyruvate [89]. It is well known
that 3BP enters cancer cells not only by specific MCTs but also by simple diffusion [61]. Therefore,
the cell permeable ability of a drug is another crucial factor on which anti-cancer therapy [90] depends.
For this reason, the pH gradient between the environment and the cancer cell cytoplasm may be
crucial for more efficient diffusion, which should be enhanced with decreasing pH. Therefore, in
therapy with 3BP some researchers suggest a hyperglycemia-inducing treatment [61]. In the context of
considering more effective anticancer therapy with 3BP, ester derivatives of this compound should be
mentioned. Among these, the most interesting seems to be 3-bromo-2-oxopropionate-1-propyl ester
(3-BrOP). Such ester derivatives of 3BP may act as typical prodrugs which are considered by many
researchers as more effective and safer therapies [90,91]. It is well known that a hydrophilic hydroxyl
or carboxyl group on the starting compound can be converted to more lipophilic esters. Such prodrugs
can be easily bio-converted to the biologically active drugs by universally present esterases throughout
the human body [92,93]. Furthermore, the desired lipophilicity can be obtained by modification of
the alkyl chain length. Such an effect was achieved in the case of a derivative of 3BP, i.e., 3-BrOP.
This potent anticancer agent is more chemically stable than 3BP and similarly to the parent compound
is also highly effective in inducing ATP depletion inside cancer cells [94]. However, it should be noted
that we still do not know whether 3-BrOP penetrates the blood-brain barrier as effectively as 3BP [95].
Another interesting solution for more effective anticancer therapy could be a novel liposomal
formulation of 3BP. This innovative form of the compound was evaluated for its permeability, inhibitory
effects on HK2, and cytotoxic potential toward the human ovarian adenocarcinoma (SKOV-3) cells.
According to recently published data, the liposomal formulation has better cell membrane permeability
and inhibitory activity toward HK2 and also results in higher cytotoxicity toward the cancer cell line
used in the study than the water solutions of 3BP [96]. Taking into account the two novel formulations
of 3BP mentioned above, further research on the safety profile of these innovations is now needed.
In conclusion, it should be emphasized that it is not easy to find effective anticancer compounds.
Ideally, the perfect anticancer agent should not only kill the primary tumor, but also any metastatic
tumors and free tumor cells present in the blood [97]. Certainly, in this regard recent developments
concerning the usage of 3BP in anti-cancer therapy provide encouragement. This is especially the
case for those cancers that clearly exhibit positive PET scans/images, i.e., those with a robust
“Warburg effect” dependent on mitochondrial bound HK2. Significantly, this includes almost all
cancer types regardless of their tissue/organ of origin.
Finally, setting cancer aside, it is important to note that 3BP has been shown to also be a
potent antifungal agent with very selective toxicity toward the human opportunistic pathogen
Cryptococcus neoformans [69,84]. Cryptococcosis takes approximately 625,000 lives each year worldwide
and on the African continent is even more frequent than tuberculosis [98]. Moreover, in vitro studies
showed that 3BP could be successfully used in combination with atovaquone against Toxoplasma gondii.
These studies also confirmed no effect of 3BP on host cell proliferation or viability [99].
2.5. Proper and Improper Use of 3BP
Finally, it should be emphasized that 3BP is a potential drug undergoing clinical
development [73,100]. When properly formulated and used to treat either animals or humans, it has
been shown to be a remarkably effective anti-cancer agent. As for any drug or other medication, 3BP
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must be properly formulated and never used in excess quantities. Unfortunately, very recently, and
certainly to the authors surprise, a non-authorized, unprofessional, and dramatic application of 3BP
by an individual with no knowledge about this small molecule and its proper formulation for use in
animals or humans has been described by Hinnerk Feldwisch-Drentrup in Science [101]. For those
skilled in the art, it is well known that drug toxicity is a question of purity (human grade) of the
compound and is directly related to the ability to properly prepare a solution of suitable composition,
concentration, formula, and pH. Please note that even the best drug used in high concentrations
can be toxic due to side and secondary effects. Certainly, 3BP at the appropriate concentration and
formulated with the correct solution choice is non-toxic to animals (mice, rats, rabbits, pigs) and
humans, effectively destroys tumors that exhibit a Warburg effect, and is therefore detected using PET
diagnostic technology. It is worth mentioning that presently in a few places in the world, including
the Dayspring Cancer Clinic in Arizona (http://www.dayspringcancerclinic.com) effective clinical
trials are being conducted for the treatment of various types of cancer using 3BP. Due to the forecasted
“epidemic of cancer” in the coming years, it is hoped that this relatively inexpensive and effective
anti-cancer and antifungal drug will pass successfully all clinical trials and will be available as soon as
possible on the shelf at pharmacies throughout the world.
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